Altiora Financial Group LLC Raises Stake in Johnson & Johnson (NYSE:JNJ)

Altiora Financial Group LLC boosted its position in Johnson & Johnson (NYSE:JNJ) by 26.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,262 shares of the company’s stock after buying an additional 474 shares during the quarter. Altiora Financial Group LLC’s holdings in Johnson & Johnson were worth $327,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. IFS Advisors LLC boosted its stake in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in Johnson & Johnson in the third quarter worth approximately $35,000. Bay Harbor Wealth Management LLC purchased a new stake in Johnson & Johnson in the fourth quarter worth approximately $32,000. Activest Wealth Management bought a new stake in Johnson & Johnson in the third quarter valued at approximately $40,000. Finally, NewSquare Capital LLC lifted its position in Johnson & Johnson by 145.8% in the fourth quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock valued at $42,000 after purchasing an additional 172 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on JNJ. Stifel Nicolaus lowered their price objective on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating for the company in a research report on Thursday, January 23rd. Raymond James lowered their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Finally, Barclays upped their target price on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Trading Up 0.6 %

NYSE JNJ opened at $166.81 on Monday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The stock has a market cap of $401.61 billion, a P/E ratio of 25.08, a P/E/G ratio of 2.56 and a beta of 0.47. The stock’s fifty day moving average price is $152.95 and its 200-day moving average price is $156.24. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the company earned $2.29 earnings per share. Johnson & Johnson’s revenue was up 5.3% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 2.97%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now directly owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.